The time is now: Autoimmune and inflammatory diseases, meet regulatory T-cell therapy
The immune system is a delicate, dynamic organ system. In February 2020, I launched Sonoma Biotherapeutics with the urgent mission to reprogram regulatory T cells (Treg) as a new medicine to treat autoimmune and other inflammatory diseases.
As I’ve been in the academic research space for decades, you may be asking yourself, why did Jeff start Sonoma Bio now? After announcing our Series A financing extension and key leadership hires earlier this week, I answer that in three complementary ways.